Primary Angle-Closure GlaucomaNCT07539675
The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis
An observational study of Primary Angle-Closure Glaucoma, run by Zhongnan Hospital at 1 site in China.
Trial summary
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Primary Angle-Closure Glaucoma
- What is being tested?
- No Additional Experimental Intervention
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2025to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.
Who may be able to join
- Clinically diagnosed with primary angle-closure glaucoma (PACG)
- Aged ≥ 50 years, no gender restriction
- Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
- Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
- Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery
Who cannot join
- Secondary glaucoma
- History of previous intraocular surgery
- Systemic diseases that can cause abnormal ocular zonules
- Other severe ocular diseases
- Long-term use of medications affecting connective tissue metabolism
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, 430000
Min Ke, doctor, 18672395959, Keminyk@163.com
About this study
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.
Read the detailed description
This study investigates the pathogenesis of PACG by conducting multi-omics analyses of aqueous humor, blood and anterior lens capsule samples from PACG patients with and without concomitant zonular abnormalities, aiming to elucidate the etiology of zonular abnormalities and uncover novel mechanisms underlying their involvement in the pathogenesis of glaucoma.
- Conditions
- Primary Angle-Closure Glaucoma
- Being tested
- No Additional Experimental Intervention
- Medical subject headings
- Glaucoma, Angle-Closure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Additional Experimental InterventionOther
No Additional Experimental Intervention
| Study group | Role | What they receive |
|---|---|---|
| Case Group A | PACG patients with zonular laxity Receives: Other: No Additional Experimental Intervention | |
| Case Group B | PACG patients without zonular laxity Receives: Other: No Additional Experimental Intervention | |
| Control Group | cataract patients without a history or signs of glaucoma Receives: Other: No Additional Experimental Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration of differentially expressed molecules in PACG patients with zonular laxity
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2026
- Study start1 Oct 2025
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Primary Angle-Closure GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Other
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zhongnan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Wen Zeng, doctor, Study director, Zhongnan HospitalNan Zhang, doctor, Study director, Zhongnan HospitalXuetian Yu, student, Principal investigator, The Second Clinical College of Wuhan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07539675
- Sponsor's protocol ID
- 20260122xrd
- Status last verified
- Apr 2026
- First submitted
- 20 Mar 2026
- Last updated
- 20 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis
- ClinicalTrials.gov ID
- NCT07539675
- Acronym / sponsor ID
- 20260122xrd
- Conditions
- Primary Angle-Closure Glaucoma
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Zhongnan HospitalUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 20 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.
Detailed description
This study investigates the pathogenesis of PACG by conducting multi-omics analyses of aqueous humor, blood and anterior lens capsule samples from PACG patients with and without concomitant zonular abnormalities, aiming to elucidate the etiology of zonular abnormalities and uncover novel mechanisms underlying their involvement in the pathogenesis of glaucoma.
Study design
- Observational model
- Case-control
- Time perspective
- Other
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Case Group A | – | Other: No Additional Experimental InterventionPACG patients with zonular laxity |
| Case Group B | – | Other: No Additional Experimental InterventionPACG patients without zonular laxity |
| Control Group | – | Other: No Additional Experimental Interventioncataract patients without a history or signs of glaucoma |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.
Key inclusion criteria (5 listed)
- Clinically diagnosed with primary angle-closure glaucoma (PACG)
- Aged ≥ 50 years, no gender restriction
- Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
- Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
- Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery
Key exclusion criteria (5 listed)
- Secondary glaucoma
- History of previous intraocular surgery
- Systemic diseases that can cause abnormal ocular zonules
- Other severe ocular diseases
- Long-term use of medications affecting connective tissue metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Additional Experimental InterventionNo Additional Experimental Intervention | Other | Case Group A, Case Group B, Control Group |
Primary outcome
Concentration of differentially expressed molecules in PACG patients with zonular laxity
Time frame: 2 years
Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Primary Angle-Closure Glaucoma
RecruitingObservational study
Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery Patients
Cataract, Primary Angle-Closure Glaucoma
Not yet recruiting
Combined Phacoemulsification-Goniotomy in Primary Open-Angle and Primary Angle-Closure Glaucoma
Primary Open-Angle Glaucoma, Primary Angle-Closure Glaucoma
Not yet recruiting
Testing a Reading Module to Improve Reading Skills and Quality of Life in Glaucoma Patients
Primary Open Angle Glaucoma (POAG), Juvenile Open Angle Glaucoma
Not yet recruitingObservational study
Predicting the Risk of Partial Ciliary Block After Cataract and Goniosynechialysis Surgery in Primary Angle-Closure Disease
Primary Angle-Closure Glaucoma
RecruitingObservational study
Vitreous Zonule in Primary Angle-Closure Glaucoma
Primary Angle-Closure Glaucoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wen Zeng, doctor study director
Zhongnan Hospital
Nan Zhang, doctor study director
Zhongnan Hospital
Xuetian Yu, student principal investigator
The Second Clinical College of Wuhan University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Primary Angle-Closure Glaucoma, run by Zhongnan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Min Ke, doctor (18672395959, Keminyk@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration of differentially expressed molecules in PACG patients with zonular laxity (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2026.